Angion Overview

  • Founded
  • 1998
Founded
  • Status
  • Private
  • Employees
  • 22
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $6.7M
Latest Deal Amount
  • Investors
  • 3

Angion General Information

Description

Operator of a biopharmaceutical company intended to develop treatments for acute kidney injury and chronic renal disease. The company's organ restoration drugs are developed using a rational drug design in order to target the body's protective, reparative and regenerative system for therapeutic benefit, thereby enabling hospitals to treat organ repair and kidney injuries efficiently.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 456 Montgomery Street
  • Suite 1200
  • San Francisco, CA 94104
  • United States
+1 (415) 000-0000

Angion Timeline

2017201820192020
Financing RoundFinancing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Angion Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 23-Jun-2020 $6.7M 0000 Completed Clinical Trials - Phase 3
6. Debt - PPP 09-Apr-2020 000.00 Completed
5. Later Stage VC 27-Jan-2020 00.000 000.00 Completed Clinical Trials - Phase 3
4. Later Stage VC 17-Jul-2018 000.00 000.00 Completed Clinical Trials - Phase 3
3. Grant 01-Jan-2017 000.00 00.000 Completed Clinical Trials - Phase 3
2. Later Stage VC (Series A) 20-Feb-2015 $4.36M $4.36M 000.00 Completed Clinical Trials - Phase 3
1. IPO 24-Oct-2014 Cancelled Clinical Trials - Phase 3
To view Angion’s complete valuation and funding history, request access »

Angion Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000 00.000000 00 0000.00 0000.00 00 0000.00
To view Angion’s complete cap table history, request access »

Angion Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biopharmaceutical company intended to develop treatments for acute kidney injury and chronic renal disease
Drug Discovery
San Francisco, CA
22 As of 2015
0000
0000000000 0 0000

0000000

olore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqu
0000 000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000

00000 00

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
000000000000000
Boston, MA
000 As of 0000
0000
0.00 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Angion Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tricida Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
00000 000000000000 Formerly VC-backed Boston, MA 000 0000 000000&0 0000
000000000 00000000 Venture Capital-Backed Rockville, MD 000.00 0000000000 0 000.00
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
You’re viewing 5 of 16 competitors. Get the full list »

Angion Executive Team (7)

Name Title Board Seat Contact Info
Jay Venkatesan MD Chief Executive Officer, Co-President and Board Member
Andrew Savadelis Chief Financial Officer
Itzhak Goldberg MD Founder, Chief Scientific Officer, Co-President and Chairman
John Neylan MD Chief Medical Officer and Senior Vice President
Prakash Narayan Ph.D Vice President of Preclinical Research
You’re viewing 5 of 7 executive team members. Get the full list »

Angion Board Members (6)

Name Representing Role Since
Allen Nissenson Angion Board Member 000 0000
Gilbert Omenn Angion Board Member 000 0000
Itzhak Goldberg MD Angion Founder, Chief Scientific Officer, Co-President and Chairman 000 0000
Karen Wilson Angion Board Member 000 0000
Victor Ganzi JD Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Angion Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Angion Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
SDL Ventures Venture Capital Minority 000 0000 000000 0
National Science Foundation Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Angion’s complete investors history, request access »